You’re projecting 100,000 cumulative customers by end of this year, and a 25k/month run rate by July 2026. That’s 300,000 new customers per year — a number that would require hypergrowth retention, perfect refill compliance, zero payer friction, and a healthcare system that bends to your Excel model.
Spoiler: it won’t.
Then you say 20x revenue multiple, while ignoring that:No ASX-listed commercial-stage biotech is valued like that.Even Telix, Neuren, and COH RMD CSL didn’t trade at 20× sales with fresh launches.BOT still hasn’t even proven sequential revenue growth, let alone breakeven.
So no —$20 isn’t realistic. check what will $20 take the Market cap be. you are so off that you can call me a loser here but you need to wake up to reality. I want to be polite but not want to take you away from dreams. its free after all without any capital gain taxes
close to $1bill AUD +/- 20% cumulative revenue from commercialisation - I am speechless here
BOT Price at posting:
29.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)